Dermata's Xyngari showed significant acne improvement in Phase 3 results. A second pivotal trial is set for the second half ...

Shares of Dermata Therapeutics, Inc. (Nasdaq: DRMA) climbed 60% following the announcement of successful Phase 3 trial results for their acne treatment, XYNGARI, ...

Dermata Therapeutics shares jumped more than 50% in early trading Thursday after the biotechnology company said its Xyngari once-weekly, topical product candidate for the treatment of ...

Topline results were announced from a phase 3 trial evaluating Xyngari (formerly DMT310), a novel topical treatment derived ...

The "clean girl" aesthetic seems innocent enough, but this exclusionary beauty standard can be incredibly isolating and disillusioning for someone like me.

Dermata Therapeutics (DRMA) announced positive topline results from the company’s first pivotal Phase 3 trial of xyngari, a novel, once-weekly, ...

Investorideas.com ( a go-to platform for big investing ideas for stock traders, including biotech stocks reports on trading ...

A recent review highlights how the Mediterranean diet can reduce inflammation and improve outcomes for chronic skin conditions like psoriasis, acne, and hidradenitis suppurativa by modulating key ...